PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 05/17/24

2024-05-17 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks...

2024-05-17 05:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-16 11:23:36 ET More on Prime Medicine FDA clears Prime Medicine to begin gene therapy clinical testing Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine Financial information for Prime Medicine ...

2024-05-15 21:30:02 ET Citigroup analyst issues BUY recommendation for PRME on May 15, 2024 07:44PM ET. PRME was trading at $6.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold recommen...

2024-05-13 13:07:36 ET More on GameStop: GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come GameStop: Compelling Risk To Reward Profile Ahead Of Q4 Earnings GameStop's sudden mem...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will partic...

2024-05-10 13:53:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prime Medicine (NASDAQ: PRME ) just reported results for the first quarter of 2024. Prime Medicine reported earnings per share of -44 cents. This was above the analyst est...

2024-05-10 08:06:25 ET More on Prime Medicine FDA clears Prime Medicine to begin gene therapy clinical testing Prime Medicine down 5%, prices $140M stock offering Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicin...

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LN...

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial ...